This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Eli Lilly & Company
Drug Names(s): Biosimilar Insulin Glargine, Abasria, LY2963016, Abasaglar (EU)
LY2963016 is a new insulin glargine product.
The drug could be filed as a biosimilar in some territories, but the company has said, in the US, it will be filed as some type of New Drug Application.
Deal Structure: In January 2011, Eli Lilly and Company and Boehringer Ingelheim announced a global agreement to jointly develop and commercialize a portfolio of diabetes compounds currently in mid- and late-stage development. Included are Boehringer Ingelheim's two oral diabetes agentslinagliptin and BI10773as well as Lilly's two basal insulin analoguesLY2605541 and LY2963016as well as the option to co-develop and co-commercialize Lilly's anti-TGF-beta monoclonal antibody.
Under the terms of the agreement, Lilly will make an initial one-time payment to Boehringer Ingelheim of euro 300 million. Boehringer Ingelheim will be eligible to receive up to a total of euro 625 million in success-based regulatory milestones for linagliptin and BI10773. Lilly will be eligible to receive up to a total of $650 million in success-based regulatory milestones on its two basal analogue insulins. Should Boehringer Ingelheim elect to opt-in to the Phase III development and potential commercialization of the...See full deal structure in Biomedtracker
Partners: Boehringer Ingelheim GmbH
Additional information available to subscribers only: